Cargando…

A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma

The present study aimed to evaluate the diagnostic and prognostic value of Tat-interacting protein 30 (HTATIP2/TIP30) levels alone and in combination with α-fetoprotein (AFP) for the evaluation of hepatocellular carcinoma (HCC) patients. ELISA and immunohistochemical measurements on the serum and ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Sha-Sha, Liao, Chu-Shu, Cao, You-De, Xiao, Pei-Ling, Deng, Tan, Luo, Rong-Cheng, Duan, Hua-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453031/
https://www.ncbi.nlm.nih.gov/pubmed/28599422
http://dx.doi.org/10.3892/ol.2017.6024
_version_ 1783240561230086144
author Fan, Sha-Sha
Liao, Chu-Shu
Cao, You-De
Xiao, Pei-Ling
Deng, Tan
Luo, Rong-Cheng
Duan, Hua-Xin
author_facet Fan, Sha-Sha
Liao, Chu-Shu
Cao, You-De
Xiao, Pei-Ling
Deng, Tan
Luo, Rong-Cheng
Duan, Hua-Xin
author_sort Fan, Sha-Sha
collection PubMed
description The present study aimed to evaluate the diagnostic and prognostic value of Tat-interacting protein 30 (HTATIP2/TIP30) levels alone and in combination with α-fetoprotein (AFP) for the evaluation of hepatocellular carcinoma (HCC) patients. ELISA and immunohistochemical measurements on the serum and tissue of HTATIP2/TIP30 protein from HCC patients and normal controls were made. Receiver operating characteristic (ROC) curve analyses of AFP and HTATIP2/TIP30 were performed, as well as logistic regression analysis of APF combined with HTATIP2/TIP30. Log-rank analysis was used to correlate the prognosis with various levels of HTATIP2/TIP30. HTATIP2/TIP30 levels were significantly lower in the HCC group compared with the control group (4.50±2.63 vs. 9.50±2.04 ng/ml, P<0.001). ROC analysis revealed an optimal cut-off point at 7.27 ng/ml HTATIP2/TIP30 for separating the HCC from the control groups. The sensitivity and specificity were 84.6 and 93.7% (P<0.001), respectively. ROC areas of HTATIP2/TIP30 (0.928, P<0.001) were significantly higher than those for AFP (P<0.001). The area under the curve of the HTATIP2/TIP30 and AFP combination was 0.950 (P<0.001). Log-rank tests revealed that the recurrence-free survival time of the group with HTATIP2/TIP30>5.71 ng/ml was significantly higher than that of the control group (P<0.001). This is the first study to demonstrate that HTATIP2/TIP30 levels in serum may be an effective biomarker for the diagnosis and prognosis of HCC.
format Online
Article
Text
id pubmed-5453031
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-54530312017-06-08 A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma Fan, Sha-Sha Liao, Chu-Shu Cao, You-De Xiao, Pei-Ling Deng, Tan Luo, Rong-Cheng Duan, Hua-Xin Oncol Lett Articles The present study aimed to evaluate the diagnostic and prognostic value of Tat-interacting protein 30 (HTATIP2/TIP30) levels alone and in combination with α-fetoprotein (AFP) for the evaluation of hepatocellular carcinoma (HCC) patients. ELISA and immunohistochemical measurements on the serum and tissue of HTATIP2/TIP30 protein from HCC patients and normal controls were made. Receiver operating characteristic (ROC) curve analyses of AFP and HTATIP2/TIP30 were performed, as well as logistic regression analysis of APF combined with HTATIP2/TIP30. Log-rank analysis was used to correlate the prognosis with various levels of HTATIP2/TIP30. HTATIP2/TIP30 levels were significantly lower in the HCC group compared with the control group (4.50±2.63 vs. 9.50±2.04 ng/ml, P<0.001). ROC analysis revealed an optimal cut-off point at 7.27 ng/ml HTATIP2/TIP30 for separating the HCC from the control groups. The sensitivity and specificity were 84.6 and 93.7% (P<0.001), respectively. ROC areas of HTATIP2/TIP30 (0.928, P<0.001) were significantly higher than those for AFP (P<0.001). The area under the curve of the HTATIP2/TIP30 and AFP combination was 0.950 (P<0.001). Log-rank tests revealed that the recurrence-free survival time of the group with HTATIP2/TIP30>5.71 ng/ml was significantly higher than that of the control group (P<0.001). This is the first study to demonstrate that HTATIP2/TIP30 levels in serum may be an effective biomarker for the diagnosis and prognosis of HCC. D.A. Spandidos 2017-06 2017-04-11 /pmc/articles/PMC5453031/ /pubmed/28599422 http://dx.doi.org/10.3892/ol.2017.6024 Text en Copyright: © Fan et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Fan, Sha-Sha
Liao, Chu-Shu
Cao, You-De
Xiao, Pei-Ling
Deng, Tan
Luo, Rong-Cheng
Duan, Hua-Xin
A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title_full A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title_fullStr A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title_full_unstemmed A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title_short A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
title_sort low serum tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453031/
https://www.ncbi.nlm.nih.gov/pubmed/28599422
http://dx.doi.org/10.3892/ol.2017.6024
work_keys_str_mv AT fanshasha alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT liaochushu alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT caoyoude alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT xiaopeiling alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT dengtan alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT luorongcheng alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT duanhuaxin alowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT fanshasha lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT liaochushu lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT caoyoude lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT xiaopeiling lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT dengtan lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT luorongcheng lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma
AT duanhuaxin lowserumtatinteractingprotein30levelisadiagnosticandprognosticbiomarkerforhepatocellularcarcinoma